Shots:

• Bayer has applied for the approval to the EMA for its pre-filled syringe to administer Eylea for five retinal indications including neovascular wet AMD- macular edema following RVO- DME- myopic CNV
• Following the state-of-the-art pre-filled syringe of Eylea is approved- it would be the new option for treatment requiring fewer steps to prepare IVT
• Eylea (solution for injection) is a recombinant fusion protein- consisting of human VEGF receptors 1&2 extracellular domains fused to the Fc portion of human IgG1- formulated as an iso-osmotic solution for IVT and has received the FDA’s approval as a prefilled syringe

Click here ­to­ read full press release/ article | Ref: Bayer | Image: Phys